Liraglutide on Ischemia-Reperfusion Injury

Methods
Study Site and Ethics
This single-center, randomized, double-blind, placebo-controlled trial was performed at the Chinese PLA General Hospital in Beijing, China. The study was approved by the Beijing Ethics Association and the Ethics Committee of the Chinese PLA General Hospital and complied with the Helsinki Declaration. All of the subjects provided written informed consent to participate in the study. The trial was registered on ClinicalTrials.gov (registration number: NCT02001363). There was a specific safety committee reviewing adverse events.
Study Population
Patients with STEMI who were admitted to the Chinese PLA General Hospital were recruited between November 2013 and October 2015. STEMI was defined as typical chest pain lasting >30 minutes within the previous 12 hours, a clear ST-segment elevation of >0.1 mV in two or more contiguous electrocardiographic leads, and elevated blood levels of troponin T. Patients were excluded for the following reasons: unconscious at presentation; cardiogenic shock, hypoglycemia, or diabetic ketoacidosis; history of myocardial infarction, stent thrombosis, or renal insufficiency; or previous coronary artery bypass surgery.
Definitions
Anterograde coronary flow in the infarct-related artery was graded according to the thrombolysis in myocardial infarction (TIMI) grading system. 13 The myocardial blush grade was assessed as described by van't Hof et al. 14 Angiographic no-reflow was defined as TIMI flow grade <3 with myocardial blush grade 0-1. 15 Hypertension was defined as blood pressure ≥140/90 mm Hg or a history of antihypertensive drug use. Diabetes mellitus was defined as fasting blood glucose level of ≥7 mmol/L or 2-hour plasma glucose value in a 75-g oral glucose tolerance test of ≥11.1 mmol/L or a history of using oral hypoglycaemic drugs or insulin. Hypoglycemia was defined as plasma glucose level of ≤3.9 mmol/L. 16 Current smoking was defined as partaking of at least 1 cigarette per day. Estimated glomerular filtration rate was calculated using the Chronic Kidney Disease Epidemiology Collaboration formula, 17 and renal insufficiency was defined as an estimated glomerular filtration rate of <60 mL/min per 1.73 m 2 . 18 Each patient's Killip classification was assigned on the basis of the severity of signs of heart failure at the time of hospital admission: Killip class 1 was defined by the absence of rales in the lung fields and the absence of an S 3 heart sound. 19 Revascularization Procedure and Medical Treatment pPCI was performed by 1 of 4 operators using standard techniques. Patients took 300 mg of aspirin in the emergency department, followed by 100 mg orally every day indefinitely thereafter. A clopidogrel loading dose (600 mg) was administered before catheterization, followed by 75 mg orally every day for ≥12 months. Drug-eluting stents were implanted as the first-line choice of stents, and the extent of no-reflow was assessed immediately after stent implantation. The data analysts were blinded of patients' TIMI scores.
Experimental Treatment Protocol
All patients were informed of the potential risks (hypoglycemia, pancreatitis, and nausea) 20 associated with GLP-1 analogs and then required to submit written informed consent before being included in the study. Patients were randomized using a computer-generated sequence to either placebo or liraglutide at a 1:1 ratio. Investigators, participants, and other study personnel were blinded to the assigned treatment for the duration of the study. Patients in the liraglutide group were treated with subcutaneous liraglutide (Novo Nordisk, Bagsvaerd, Denmark), whereas patients in the control group were given subcutaneous placebo (Novo Nordisk). The treatment started 30 minutes before pPCI with a dose of 1.8-mg liraglutide or placebo administered in the ambulance. After admission, patients were treated with 0.6-mg liraglutide once daily for 2 days, then 1.2-mg liraglutide for another 2 days, followed by 1.8-mg liraglutide for 3 days. These dosages correspond, respectively, to 1.6, 3.2, and 4.8 pmol/kg per minute based an ideal 70kg patient. In 50 consecutive patients, blood samples were collected at the end of the pPCI procedure to measure the liraglutide plasma concentration in the patients randomized to liraglutide treatment (normal range, 0.03-0.3 nmol/L). 9 The blood sample was collected from the femoral sheath at the end of the procedure. Medications including aspirin, statins, β-blockers, and others were begun on admission, and all patients continued these drugs during the 3-month period. Oral glucose tolerance test was performed before discharge (usually on day 6). The patients with diabetes mellitus received similar antidiabetic treatment after discharge. Good clinical practice training was required for all personnel involved in the trial.
Study Outcomes
The primary efficacy variable was the salvage index measured by CMR at 3 months. Secondary efficacy variables were final infarct size after 3 months, the prevalence of no-reflow after percutaneous intervention, and the levels of high-sensitivity C-reactive protein (hsCRP), interleukin-6, superoxide dismutase, malondialdehyde, endothelin-1 (ET-1), and nitric oxide (NO) levels assessed before the intervention and after 3 months.
Laboratory Tests
Blood glucose was measured before intervention and every 4 hours after admission. hsCRP levels were measured using a sandwich enzyme-linked immunosorbent assay (R&D Systems Inc, Minneapolis, MN; intra-assay coefficient of variation 3.2%, interassay coefficient of variation 3.5%; normal range, <0.8 mg/dL).
Cardiac Magnetic Resonance
An initial scan was performed during the index admission to assess the myocardial area at risk (AAR). 21, 22 A second scan was performed 91±5 days later to assess the final infarct size. CMR was performed on a 1.5-T Signa Excite HD MR Scanner (GE Healthcare Systems, Milwaukee, WI).
Myocardial AAR and Salvage Index
The myocardial AAR was assessed on the first CMR scan as edema using a T2-weighted short tau inversion-recovery sequence ( Figure 1A ). 21 Multiple slices in the short-axis image plan were acquired to cover the entire LV. The CMR data were analyzed by 2 CMR readers who were blinded to both randomization and timing of the recordings, using the freely available validated cardiovascular image analysis software package Segment v1.9 (http://segment.heiberg.se). 22 The endocardial and epicardial borders were manually traced in each short-axis image, and LV mass was calculated without incorporation of the papillary muscles and slow-flowing blood in the trabeculae. AAR was defined as the hyperintense area on T2-weighted images. A myocardial area was regarded as hyperintense when the signal intensity was higher than 2 SD of the signal intensity in the normal myocardium. The signal intensity in the normal myocardium was determined by tracing an area of at least 10 pixels within the normal myocardium. Hypointense areas within the AAR were considered part of the AAR. The salvage index was calculated as follows: (AAR,g-infarct size, g)/ AAR, g. The same 2 experienced CMR readers validated the method used to assess salvage index, and intra-and interobserver variability were 0.01±0.03 and 0.02±0.05, respectively.
Infarct Size and Left Ventricular Ejection Fraction
The final infarct size was evaluated on the second scan with delayedenhancement CMR ( Figure 1B ). 23 Images were obtained ≈10 minutes after intravenous injection of 0.1 mmol/kg body weight gadoliniumdiethylenetriaminepentaacetic acid (Gadovist, Bayer Schering, Berlin, Germany) as an ECG-triggered inversion-recovery sequence. In a single slice, the inversion time was adjusted to null the signal from the normal myocardium. Multiple slices in the short-axis image plan were acquired to cover the entire LV, and the final infarct size was assessed using the Segment v1.9 postprocessing tool. The endocardial and the epicardial borders were manually traced in all short-axis images, and the LV myocardial mass was then calculated. Papillary muscles were considered part of the LV cavity. The infarct size was defined as the hyper-enhanced myocardium on the delayed-enhancement images, expressed in grams and in percentage of the total LV mass.
Left ventricular ejection fraction (LVEF) was assessed by CMR on an ECG-triggered balanced steady-state-free procession cine sequence by applying multiple slices in the short-axis image plan covering the entire LV. On cine short-axis CMR images, the LV volume was calculated by manually tracing the endocardial borders in all 25 phases. The diastolic and systolic frames were automatically identified according to the size of the LV blood pool area, and LVEF was calculated accordingly. Papillary muscles were included in the LV lumen.
Clinical Follow-Up
There was a prespecified outpatient follow-up visit per protocol at 6 months. Follow-up information on the study population was obtained during a patient visit at the outpatient clinic or from a review of the medical records. Major adverse cardiovascular events were defined as repeat revascularization, nonfatal myocardial infarction, and cardiac death.
Statistical Analysis
According to Lønborg et al's 9 study of exenatide, we assumed an average difference in salvage index between the liraglutide and the placebo of 0.09 (SD=0.12) and estimated a sample size of 36 subjects in each study group to achieve a power of 80% to demonstrate superiority of liraglutide arm over the control arm in the primary end point with 2-tailed α<0.05. On the assumption that ≈80% of randomized patients would complete the trial; we planned to recruit 90 patients (45 patients per arm).
Continuous variables are expressed as mean±SD or median as appropriate. After testing data for normality, we used the independent t test or Mann-Whitney U test to compare values between the liraglutide group and the control group. Comparisons of categorical data between groups were made with the χ 2 test, and the laboratory parameters (hsCRP, superoxide dismutase, and ET-1) were assessed by 2-way ANOVA. To compare the relationship between the AAR and the infarct size, a regression analysis was performed, and an analysis of covariance was used to test for the equality of the regression lines for the liraglutide group and the placebo group.
To test the relationship between the difference in salvage index and the difference in change in fasting glucose or hsCRP, we performed multiple regression after adjusting for age, sex, smoking cessation, hypertension (yes/no), hyperlipidemia (yes/no), diabetes mellitus (yes/ no), symptom-to-balloon time, anterior infarct (yes/no), preinfarct angina, Killip class, troponin T, hemoglobin, estimated glomerular filtration rate, body mass index, β-blocker (yes/no), angiotensin-converting enzyme inhibitor (yes/no), no-reflow (yes/no), thrombectomy (yes/ no), metallic coronary stent (yes/no), coronary artery bypass grafting (yes/no), and intra-aortic balloon pumping (yes/no). The significance level was set at P<0.05. Statistical analyses were performed using SPSS software version 18.0 (SPSS, Chicago, IL).
Results Patients
A total of 184 patients with STEMI undergoing emergency pPCI were screened for inclusion, of whom 88 patients were not eligible for the following reasons: renal insufficiency (13), a history of myocardial infarction (27) , cardiogenic shock (7), previous coronary artery bypass grafting (4), no myocardial infarction (15) , and study refusal (22) . Ninety-six patients were randomized 1:1 to receive either liraglutide or placebo for 7 days. A final number of 77 patients met the inclusion criteria and were eligible for analysis ( Figure 2 ).
One patient had de novo diabetes mellitus diagnosis in the liraglutide group, and 2 patients had de novo diabetes mellitus diagnosis in the control group. The clinical characteristics of the 2 groups are shown in Table 1 . There were no significant differences in age, sex, medical history, symptomto-balloon time, anterior infarct, Killip class 1, or troponin T levels between the 2 groups (Table 1) . Moreover, the use of statins, β-blockers, aldosterone antagonists, and angiotensinconverting enzyme inhibitors was not significantly different between the 2 groups.
Plasma concentrations of liraglutide were collected from 22 patients who were randomized to liraglutide. The mean plasma concentration of liraglutide was 0.121±0.058 nmol/L.
Salvage Index and Infarct Size
At 3 months, the primary end point, the difference in salvage index between the liraglutide group (n=39) and the placebo group (n=38) was +0.11 (95% confidence interval, +0.02 to +0.19; P=0.001). In a multivariable analysis adjusting for a history of preinfarct angina and angiographically detected collaterals, the difference in salvage index between the treatment groups remained statistically significant (P=0.004). The final infarct size was lower in the liraglutide group than that in the placebo group (Table 2; Figure 3A ). The infarct size/ AAR ratio was 24% smaller in the liraglutide group. In the regression analysis of infarct size plotted against the myocardial AAR, the line for the liraglutide group was significantly below the line for the placebo group (P=0.02; Figure 3B ).
In patients with infarctions in the area supplied by the left anterior descending artery (liraglutide group: n=14; control group: n=13), the salvage index was 22% larger in the liraglutide group than that of the placebo group (P=0.04), and the final infarct size/AAR ratio was 21% smaller (P=0.06). In the subgroup with nonanterior infarct location, we also found a larger salvage index in the liraglutide group (P=0.03). There was a nonsignificant improvement similar to the overall result in diabetic patients.
There was no significant difference in LVEF by CMR on the first CMR between the 2 groups (51.3±8.1% versus 50.7±7.6%, P>0.05). LVEF measured by echocardiography was significantly higher in the liraglutide group than in the control group at 7 days (58.2±9.2% versus 54.5±9.0%, P=0.04). LVEF assessed by CMR at 3 months was significantly different between the 2 groups (P=0.008).
Fasting Glucose, hsCRP, Superoxide Dismutase, ET-1, and NO Levels
Fasting glucose levels decreased from 8.5±3.1 to 6.1±1.5 mmol/L in the liraglutide group and from 8.4±3.4 to 6.7±1.4 mmol/L in the control group at day 7. The difference in change of fasting glucose levels between the liraglutide and control groups was significant (P<0.05). The troponin T levels were significantly lower in the liraglutide group than in the control group at 5 days (0.2±0.1 versus 0.4±0.1 ng/mL, P<0.001). The mean reductions in serum hsCRP levels were also significantly greater in the liraglutide group than in the control group (Table 3) . The difference in the decrease in serum hsCRP levels was −0.24 mg/dL (95% confidence interval, −0.38 to −0.09; P<0.001). The difference in the decrease in ET-1 levels between the 2 groups was −0.12 µg/L (95% confidence interval, −0.27 to −0.01). In contrast, NO synthase activity increased significantly in the liraglutide group (difference: +0.97 U/mL; P<0.001), as did the serum NO levels (+8.1 µmol/L; P<0.001). No effects of liraglutide on blood pressure (P=0.25) and heart rate (P=0. 36) were seen in patients. The difference in salvage index between the 2 groups correlated negatively with the difference in change in serum fasting glucose level (γ=−1.44, P=0.02) and hsCRP level (γ=−0.67, P=0.03) in adjusted analyses.
Safety
Hypoglycemia occurred in 3 of 49 patients (6%; 1 diabetic patient and 2 nondiabetic patients) in the liraglutide group and 1 of 47 patients (2%; 1 diabetic patient) in the control group. Nausea was reported in 4 of 49 patients (8%) in the liraglutide group and in 2 of 47 patients (4%) in the control group. Diarrhea occurred in 1 of 49 patients (2%) in the liraglutide group and in 1 of 47 patients (2%) in the control group. There was no observed case of acute pancreatitis during the study.
Events During the 6-Month Follow-Up Period
During the 6-month follow-up period, the incidence of major adverse cardiovascular events was not significantly lower in the liraglutide group than in the control group (P=0.34). There were no significant differences in the incidence of myocardial infarction, repeated revascularization, or cardiac death ( Table 4 ). The death was unrelated to liraglutide treatment.
Discussion
Our study shows that liraglutide is associated with improved myocardial salvage index and reduces infarct size. Liraglutide administration also led to favorable changes in markers of inflammation and endothelial function.
There are several important differences between this study and previous studies. First, the current submission focuses on reperfusion injury (potential mechanisms of the cardioprotective effect), whereas our previous study focuses on LV function. 11 Reperfusion therapies could limit infarct size. 2 In this study, we found that liraglutide improved infarct size after STEMI, possibly by reducing reperfusion injury. There was not any overlap of patients between the 2 studies. Second, we also found that liraglutide was associated with less early no reflow in another study, 24 but no-reflow was only measured by the TIMI flow grade and myocardial blush grade. This may be a subjective end point. Magnetic resonance imaging scanning might give a more objective sense of the microvascular damage. Third, it has previously been demonstrated that an increased salvage index is associated with an improved clinical outcome in patients with STEMI. 25
Figure 2. Study protocol. CABG indicates coronary artery bypass surgery; and CMR, cardiac magnetic resonance. Liraglutide on Ischemia-Reperfusion Injury
The study was not powered to show a significant difference in infarct size. With a difference of 6 g in infarct size and an SD of 12 g, a total of 115 patients would be needed in each group to detect a significant difference. The salvage index was chosen as primary end point. Fourth, mean length of stay for the AMI hospitalizations was 7 days. 26 A short 7-day course of liraglutide in STEMI patients is associated with improvement in LVEF at 3 months in our previous study. 11 So a 7-day treatment period was chosen in this study. In addition, the median door-to-balloon time was 75 minutes in our study. The door-to-balloon time in Beijing was also quite long (80 minutes). 27 Guidelines in China recommend a doorto-balloon time of <90 minutes for patients with STEMI who undergo pPCI. 28 And there were no significant differences in symptom-to-balloon time and door-to-balloon time between the liraglutide and control groups. Data are presented as mean value±SD or median (range: 25%-75%) or number or percentage (%) of patients. ACEI indicates angiotensin-converting enzyme inhibitor; CABG, coronary artery bypass grafting; CMR, cardiovascular magnetic resonance; eGFR, estimated glomerular filtration rate; IABP, intraaortic balloon pumping; MBG, myocardial blush grade; and TIMI, thrombolysis in myocardial infarction. 
Previous Research
The effect of GLP-1 on reperfusion injury has been researched recently. Kristensen et al 29 found that liraglutide has a neutral effect on myocardial infarct size in a porcine ischemia-reperfusion model. A negative result with exenatide was also found in Bernink et al's 30 study. But in patients with STEMI, adjunctive exenatide therapy with pPCI was associated with a reduction in infarct size and improved subclinical LV function. 10 Lønborg et al 9 found that administration of exenatide at the time of reperfusion increased myocardial salvage in patients with STEMI undergoing pPCI. 9 The remarkable CMR results of this study are greater in magnitude and significance than that in the study by Lønborg et al 9 (which used exenatide). The differences in the subjects (door-to-balloon time was 75 minutes), the nature of the agent (a long-acting GLP-1 mimetic), and the duration of treatment (7 days) might be responsible for this. Our study adds the following incremental information to what has already been published on this topic. First, the duration of the use of GLP-1 in our study was longer than previous studies. 9,10 Second, infarct size was improved with liraglutide in patients with STEMI (−6 g, P=0.05). Regarding adverse effects, no significant differences were found between the liraglutide and control groups. Third, before coming to the hospital, patients with AMI cannot receive intravenous therapy, but the subcutaneous administration is feasible and desirable; therefore, our protocol may have many practical advantages for patients. We also found that liraglutide could reduce inflammation and improve endothelial function.
In the Fernandez-Jimenez et al study, 31 myocardial edema during the first week after ischemia/reperfusion follows a bimodal pattern. The initial wave appears abruptly upon reperfusion and dissipates at 24 hours. Conversely, the deferred wave of edema appears progressively days after ischemia/reperfusion and is maximal around day 7 after reperfusion. 31 In our study, CMR was performed at 35±12 hours, edema occurred in the ischemic zone, and was similar between the 2 groups. In addition, interventions 32 In the study, more cardioprotection is also observed with anterior infarcts.
Potential Mechanisms
Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome. 33 Hyperglycemia can increase ET-1 secretion in endothelial cells and aggravate myocardial infarction, 34 and GLP-1 is an incretin hormone that has been shown to promote myocardial glucose uptake. 35 GLP-1 may also modulate glucose levels, improve myocardial infarction, and increase salvage index. 36 The mechanisms of ischemia-reperfusion injury involve inflammation and endothelial dysfunction. 37 GLP-1 was reported to ameliorate inflammation. 38 In our study, we found that hsCRP levels were significantly lower in the liraglutide group; therefore, it is possible that liraglutide reduces inflammation and increases salvage index. GLP-1 can ameliorate endothelial dysfunction. 39 In this study, the NO and NO synthase levels in the liraglutide group were significantly higher than those in the control group, and the administration of liraglutide led to a reduction in serum ET-1 levels. Therefore, it is possible that improved endothelial function contributed to the increase in salvage index in the liraglutide group. However, the underlying mechanism requires further investigation.
Study Limitations
This study has several limitations. First, the main limitation is that the study involved a single center with a small sample size. Thus, the results should be interpreted with caution. Our study added to growing data and supports the hypothesis that GLP-1 agonists can play a significant role in preventing reperfusion injury in STEMI patients, which should be evaluated by large multi-center trials. Second, short tau inversion recovery technique was used to quantify edema. It may give a false signal, especially in areas of blood pooling, particularly in the case of patients with poor LV function. It has been suggested that to avoid this bias, one could use a multislice technique. 40 Third, the CMR 1 was later on the control group so edema could not be present just because it was done later than the liraglutide group. The number of patients could be increased to try to minimize this effect.
Conclusions
Liraglutide improves myocardial salvage and infarct size after STEMI, possibly by reducing reperfusion injury, making it a promising treatment for evaluation in larger trials. 
